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Abstract
Telomerase, a reverse transcriptase primarily devoted to the elongation of telomeres in
mammalian cells, is also the first bona fide common tumor antigen. In fact, telomerase is over-
expressed in > 85% of tumor cells irrespective of origin and histological type. In the past seven
years, there has been considerable interest in assessing telomerase as substrate for vaccination in
cancer patients to induce CD8 T cell responses. Because the activation of T cells is restricted by
the MHC molecules on antigen presenting cells or tumor cells, the identification of telomerase
peptides immunogenic for humans is tightly linked with HLA types. To date, a handful of peptides
have been identified through a variety of screening procedures, including bioinformatics prediction,
in vivo immunization of HLA transgenic mice, in vitro immunization of PBMC from normal donors
and cancer patients, and processing in human tumor cells. Currently, there exist putative peptides
for five major HLA types (A2, A1, A3, A24 and B7). Due to the complexity of the HLA system,
trials have been performed focusing on the most prevalent HLA type, HLA-A2. Here, we
summarize this collective effort and highlight results obtained in Phase 1 trials including a Phase 1
trial performed at the UCSD Cancer Center.
Background
Active immunization (vaccination) offers the greatest
advantages to prevent or control disease. Applied to the
control of cancer, this concept is referred to as therapeutic
vaccination. In the past decade great effort was placed
exerted to identify tumor associated and tumor specific
antigens [1,2] and to develop efficient methods to vacci-
nate cancer patients [3-6]. By and large, efforts have been
directed at inducing T cell mediated responses, and partic-
ularly major histocompatibility complex (MHC) Class I-
restricted cytotoxic CD8 T lymphocytes. Tumor associated
antigens can be clustered in major categories. Tradition-
ally, they were regarded as onco-developmental antigens
mainly carbohydrate in nature [7]. Subsequently, new
families of antigens were identified. These include tissues
specific antigens, i.e., antigens found principally in one
type of tumor cells, e.g., melanoma cells, prostate cancer
cells, pancreatic tumor cells etc. A second group of is anti-
gens is shared by a variety of tumors such as certain onco-
genes (e.g., p53 NY-ESO1, MUC.1, and Her2-neu). These
shared antigens cover a larger segment of the tumor pop-
ulation. A third family comprises antigens that are com-
mon to most or all tumor cells irrespective of their origin
and histological type. These are molecules intimately
associated with cellular processes common to all tumor
cells such as immortalization or survival. Finally, there are
viral antigens in tumor cells that viral antigens in those
cases where a viral pathogenesis is at play (e.g., HPV, HBV
and EBV).
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In this review article we will recapitulate the history of one
such effort as it relates to the discovery and immunologi-
cal characterization of the first bona fide common tumor
antigen, telomerase reverse transcriptase [8]. More impor-
tantly, the emphasis will be to demonstrate in how little
time a handful of laboratories around the world interested
in this new antigen converted their bench studies into
bedside therapeutic vaccination intervention.
Telomerase from cell proliferation to cell immortalization 
and cancer
To complete the replication of chromosomal ends, cells
have evolved developed a specialized reverse transcriptase
called telomerase [9], which adds a repeated sequence
onto the ends of newly replicated chromosomes. Telom-
erase is a ribonucleoprotein, which consists of a protein
component (TRT) and an RNA component (TR) contain-
ing the template for synthesis of the repeat unit added
onto the ends of chromosomes [10]. Telomeres, the distal
ends of eukaryotic chromosomes, stabilize the chromo-
somes during replication [11-13]. Telomeres shorten pro-
gressively with successive cell divisions and this
shortening of chromosomal ends decreases the replicative
potential of cells eventually leading cells into senescence
or into crisis, which results in cell death [14]. In addition
to preventing the shortening of telomeres, telomerase has
been shown to protect the single-stranded ends of chro-
mosomes and may have a role in maintaining telomeres
in a structure that is not recognized as DNA damage,
thereby preventing activation of the cellular senescence
program [15]. In turn, maintenance of a constant tel-
omere length ensures chromosomal stability, prevents
cells from aging, and confers immortality [16-18]. This
rule applies to all somatic cells. Two diseases character-
ized by severely premature aging, progeria and Werner's
syndrome, are characterized by cells that divide only a
fraction of the times normal somatic cells divide due to an
abnormal telomere dynamics.
The connection of telomerase with cancer is striking. On
the one hand, mice lacking telomerase RNA show that tel-
omerase activation is a key event in malignant cell trans-
formation [19-21]. On the other hand, in vitro studies in
human cells show that the long-term ectopic expression of
telomerase in normal fibroblasts is sufficient for immor-
talization but not malignant transformation [22]. How-
ever, the expression of telomerase in combination with
two oncogenes (SV40 T antigen and Ras) promotes tumor
transformation in normal human epithelial and fibrob-
last cell lines [23]. These transformed cells form tumors in
nude mice. Thus, although telomerase per se is not tumor-
igenic, it plays a direct role in oncogenesis by allowing
pre-cancerous cells to proliferate continuously and
become immortal. New evidence shows that a viral telom-
erase RNA gene encoded by the Marek's diaease virus, an
oncogene in chickens, promotes tumor formation [24].
The PCR-based TRAP assay [25] reveals a striking correla-
tion (>85%) between high telomerase activity and tumors
of different histological origins and types [26,27]. In con-
trast to cancer cells, normal somatic cells display little or
no telomerase activity [26,28].
As anticipated above, telomerase is the first bona fide com-
mon tumor antigen. The history of telomerase as tumor
antigen began with work in the laboratory of Lee Nadler
and in our own laboratory [29,30] with the identification
of 9 mer peptides of the human telomerase reverse tran-
scriptase (hTRT) that could serve as immunogens to acti-
vate CD8 T cell precursors and generate cytotoxic T
lymphocytes (CTL). This will be reviewed below.
T cell responses against tumor and the issue of tolerance
Immunologically mediated anti-tumor responses can be
attributed to a variety of mechanisms and cell types.
Among the latter both NK and T lymphocytes are able to
deliver a cytotoxic attack to tumor cells. However, only T
cells do so by recognizing a specific antigen on the target
cell and they are also capable of generating memory
responses after initial expansion by antigen. Among T cell
responses, CD8 T lymphocytes have received the greatest
attention. These cells recognize antigen peptides of dis-
crete size (8–10 amino acids) in the context of the MHC
molecule. For this reason we, like others, have concen-
trated on CD8 T cell responses against telomerase.
The activation of CD8 T lymphocytes requires two signals:
recognition of tumor antigen peptides in association with
the MHC molecule and co-stimulation, a complex series
of positive signals imparted to placed upon the T cell by
the antigen presenting cell (APC) (or by the tumor cell). It
is well appreciated that recognition of antigen in the
absence of costimulation leads to anergy of the T cells
[31], a problem often encountered in T cell responses
induced by vaccination in cancer patients. Given these
constraints T cell activation also depends on (a) the avail-
ability of antigen in the right form and dose, (b) the func-
tion status of the APC, and (c) the spatio-temporal
relation between the APC and responding CD8 T lym-
phocytes in secondary lymphoid organs [32].
CD8+ T lymphocytes have been documented as part of a
natural response to tumor antigens in patients with cancer
[33-35]. Most tumor antigens, however, are cellular com-
ponents, which are encoded in the genome of the individ-
ual. They are by definition self antigens. Therefore, the
immune system ability to generate immunity against
tumor self antigens rests on its ability to overcome self tol-
erance whether this be central [36] or peripheral
(reviewed in [37]). Self tolerance may exert its toll on the
tumor antigen-specific T cell repertoire before cancerJournal of Translational Medicine 2007, 5:12 http://www.translational-medicine.com/content/5/1/12
Page 3 of 17
(page number not for citation purposes)
appears and may hamper the development of efficient
anti-tumor T cell responses [38]. The hypothesis that tol-
erance shapes the T cell repertoire directed at tumor anti-
gens expressed even at low levels in normal tissues,
leaving behind T cells with low affinity receptors for anti-
gen, was demonstrated in mice transgenic for the human
p53 tumor antigen [39,40]. Fortunately, vaccination can
expand the pool of low avidity T cells and this can control
tumor growth [41]. The lesson from these studies is that
in all likelihood tolerance to tumor antigens is not com-
plete and that the low avidity T cells that have escaped tol-
erance and constitute the "residual T cell repertoire" can
be reactivated and expanded in vivo by suitable vaccina-
tion.
Identification of immunogenic peptides of human 
telomerase
The quest for telomerase as an antigen for cancer began
with a few basic questions in mind: "Are there peptides
from the consensus sequence of human TRT that bind
with sufficient avidity MHC molecules and is there a resid-
ual CD8 T cell repertoire against hTRT in humans?" "Can
telomerase peptides generate CTL responses that kill
across tumor types?" and "Is there a residual repertoire in
cancer patients?" Studies were performed using as a main
approach the in vitro generation of specific CTL starting
from peripheral blood mononuclear cells (PBMC). We
identified two peptides selected on the basis of high bind-
ing to the HLA-A2 molecule: 540ILAKFLHWL548  and
865RLVDDFLLV873, since termed p540 and p865. The
same p540 was identified and analyzed in depth by
Vonderheide et al [29]. While both groups found that nor-
mal individuals respond to immunization with telomer-
ase peptides, only our laboratory showed the induction of
specific CTL in cancer patients. Notably, CTL generated in
vitro  against both peptides killed peptide-pulsed target
cells and tumor cells in a MHC-restricted fashion (Table
1). To complete the characterization, p540 and p865 were
assessed for their immunogenicity in vivo using HLA A2.1
transgenic mice [42], as in these mice the peripheral CD8+
T cell repertoire is essentially educated on the transgenic
human molecule. Both peptides induced specific CTL
responses [30], although differences were noted in that
p540 induced CTL in a higher proportion of cases and
CTL had greater lytic activity.
Following these initial reports, information on the immu-
nogenicity of telomerase peptides accumulated rapidly.
To date, immunogenic peptides have been identified for
five HLA class I alleles (HLA-A*0201, B*0702, A*0101,
A*0301 and A*2401) (Table 2). All of these peptides were
predicted from the 1132 amino acid telomerase sequence
using either one or both of two MHC binding predictive
algorithms (SYFPEITHI and BIMAS) [43,44]. Actual MHC
binding assays refined the prediction in the majority of
cases. In vitro immunization of PBMC has been a constant
aspect of all these studies, but in vivo immunogenicity in
HLA transgenic mice has been used in a handful of reports
only in the case of HLA-A2, HLA-B7 and HLA-A24
restricted peptides (Table 3). 51Cr-release assay and intra-
cellular staining for IFN-γ synthesis or ELISPOT as a
marker of CD8 T cell activation. As indicated in Table 2, a
variety of model tumor cells representative of different tis-
sues (i.e., breast, prostate, lung, colon, kidney and liver)
were tested. For four peptides, information also exists
with relation to tetramer positivity by the responding CD8
T cells. Since tetramer positivity correlates with the CTL
induction, this approach proved useful to monitor spon-
taneous activation of specific CD8 T cell precursors during
the development of cancer. As it will be discussed below,
it is also a marker of immunological response in clinical
trials. To the best of our knowledge, the information dis-
Table 1: Cancer cells of different origin and type are killed by anti-hTRT CTL
Cell Target Tumor Origin Telomerase Activity HLA-A2 Percent Lysis
CTL p540 CTL p865
T2+peptide ND Pos. 59 48
T2 ND Neg. 11 4
MCF7 Breast Pos. Pos. 39 41
SKBR3 Pos. Neg. 7 9
SW480 Colon Pos. Pos. 12 37
HCT011 Pos. Neg. 9 6
H69 Lung Pos. Pos. 41 9
H146 Pos. Neg. 11 5
624 Melanoma Pos. Pos. 48 39
1351 Pos. Neg. 12 6
LnCap Prostate Pos. Pos. 44 41
PC3 Pos. Neg. 9 5
From ref [30].Journal of Translational Medicine 2007, 5:12 http://www.translational-medicine.com/content/5/1/12
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cussed above and summarized in Tables 2 and 3 repre-
sents the breadth of our current understanding of the
immunogenicity of human telomerase peptides.
Based on the foregoing, several conclusions can be made.
The first is that the prerequisite that CTL against telomer-
ase would kill tumor cells of different origin and type was
verified, consistent with the idea that telomerase is a com-
mon tumor antigen. The second is that humans possess a
residual CD8 T cell repertoire directed at telomerase. Sur-
prisingly, on average it appears that the response rate in
cancer patients is equal to if not higher than that of nor-
mal donors. Of note, assessing immunogenicity of telom-
erase peptides required the combined use of different
approaches. In selected instances, the same peptide was
identified by groups working independently, validating
the general understanding that telomerase is indeed
immunogenic in humans.
In vitro studies in cancer patients
Cancer patients responded to in vitro immunization at a
surprisingly high rate (Table 2). It was then important to
answer the question: "Did the response rate differ in
patients with different types of cancers? " The response in
cancer patients has been assessed in four HLA types: HLA-
A2, HLA-B7, HLA-A3 and HLA-A24 (Table 3). Overall, all
cancer patient categories responded albeit noticeable dif-
ferences were found depending on the type of cancer. For
instance, patients with colorectal or liver cancer were
found to respond poorly compared with to patients with
prostate, breast, lung cancer or melanoma. While it is dif-
ficult to determine if this is due to technical differences
among laboratories, differences in response in various
HLA groups or simply differences among patients, it is
clear that this issue requires further work. It should be
noted, however, that irrespective of the response rate, in
some of the studies CTL generated in vitro against telom-
erase lysed autologous primary cancer cells (Table 3). Of
note, in liver biopsies it was found that some tetramer
positive tumor infiltrating lymphocytes were found sug-
gesting an active recruitment of telomerase-reactive CD8 T
cells at the tumor site. This type of analysis should be per-
formed more systematically whenever possible to assess
the extent to which telomerase-specific immunity contrib-
utes to the general anti-tumor response that is enriched at
the tumor site.
Phase 1 trials
A synopsis of the Phase 1 trial conducted and published
to date is provided in Table 4. A telomerase-specific
immune response following therapeutic vaccination was
first reported by Su et al [45] in patients with metastatic
renal carcinoma vaccinated with autologous dendritic
cells transfected with renal tumor cell derived mRNA
(Table 4). In this trial, a great proportion of patients
responded immunologically as determined by ELISPOT
analysis and a 51Cr-release assay using mRNA renal tumor
transfected dendritic cells as targets or stimulators respec-
tively. Although, in this trial patients were not specifically
vaccinated against telomerase, a telomerase specific
response was measured, arguing for the presence of telom-
erase mRNA as a component of total tumor cells mRNA
along with the mRNA of other tumor antigens. In four of
the five subsequent Phase 1 trials, patients were immu-
nized against the high affinity, HLA-A2 restricted p540 tel-
omerase peptide. Each trial used a different vaccination
strategy. Thus in one case, renal, and colon cancer, and
melanoma cancer patients were vaccinated with p540 in
incomplete Freunds' adjuvant (IFA) [46]. In a second trial,
prostate and breast cancer patients were vaccinated with
dendritic cells (DCs) pulsed with p540 and KLH as a
source of T helper cell determinants [47]. Non-small cell
lung cancer patients were vaccinated with soluble p540 in
GMC-SF in conjunction with a second telomerase pep-
tide, p613, a promiscuous HLA-DR, HLA-DQ and HLA-
DP biding peptide as a source of T cell help [48]. In the
trial performed at UCSD, which will be discussed in detail
below, prostate cancer patients were vaccinated with
autologous transgenic B lymphocytes, a new vaccine
approach tested for the first time in humans in this trial,
targeting the immune response against p540 and pY572
[49] (see also Table 2). Finally, Su et al [50] vaccinated
metastatic prostate cancer patients with dendritic cells
transfected with telomerase mRNA. As indicated in Table
4, the immunological response averaged between 40–
100% in all but one trial. In the report by Brunsvig et al.
[48] only 2 out of 24 patients (8%), responded to the high
affinity p540 telomerase peptide. A possible explanation
for this low response rate may be due to the lack of pre-
selection of patients based on HLA typing. A larger
number of patients (11/24) did, however, respond to the
MHC Class II peptide. Collectively it appears that an
immunological response after vaccination was detected in
the majority of vaccines irrespective of the modality of
vaccination, confirming earlier conclusions that cancer
patients have a residual repertoire of telomerase specific
CD8 T cell precursors that can be expanded in vivo by vac-
cination.
The phenotype of the induced CD8 T cell responses was
also characterized in two trials. In one case, responding
cells were found to be CD45RA+/CD45RO+/CCR7-/
CD27+/CD28+ corresponding to an effector memory cell
phenotype [47] whereas in the other case, they were
CD45RA+/CD45RO-/CCR7-/CD27-  corresponding to an
effector cell phenotype [50]. Finally, consistent with the
fact that all these trials were Phase 1 trials with a target
patient population with advanced stage cancer, clinical
responses were found in only a limited number of cases.
Thus, a partial clinical response was reported for 1 of 5J
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Table 2: Identification, Analysis and Characterization of HLA-restricted Telomerase Peptide
HLA allele hTRT peptide Sequence In vivo peptide immunization 
in HLA Tg mice R/T
In vitro immunogenicity in 
PBMC
Tet Killing of tumor cells (hTRT+HLA+)R e f .
Normal 
donors
Cancer 
patients
51Cr- release assay IFNγ/ELISPOT
A*0201 p540 ILAKFLHWL 8/10 11/12 9/13 + T2*, LnCap, MCF-7, H69 624, SW480 ND [30]
ND 5/5 ND + T2*,36 M, U266, IM9, SKW6.4, K029 ND [29]
ND ND 5/6 + T2*, U266, IM9, K029, SKMEL2 ND [66]
ND ND 21/23 + T2*, BJAB, LnCap ND [67]
ND 0/12 5/37 ND ND + [68]
ND 4/20 11/14 ND ND + [69]
p865 RLVDDFLLV 7/10 7/10 5/9 + T2*, LnCap, MCF-7,624, SW480 ND [30]
ND 0/12 4/37 ND ND + [68]
ND 2/20 6/14 ND ND + [69]
p572 RLFFYRKSV ND 0/3 1/4 ND T2* ND (unpublished 
data)
pY572 YLFFYRKSV 7/7 4/6 5/8 + T2*, U266, HELA-HHD ND [49]
B*0702 p277 RPAEEATSL 4/6 7/8 ND ND T2-B7*, T1-B7, JY, Jurkat ND [70]
5/6 5/8 ND ND ND ND [70]
p342 RPSFLLSSL 2/6 2/8 ND ND T2-B7*, T1-B7, JY, Jurkat ND [70]
4/4 5/8 ND ND ND ND [70]
p351 RPSLTGARRL 5/6 6/8 ND ND T2-B7*, T1-B7, JY, Jurkat, LB34, KUL68, U293T ND [71]
p444 DPRRLVQLL 2/7 1/8 ND ND ND ND [70]
p464 FVRACLRRL 4/4 3/8
p1107 LPGTTLTAL 2/4 5/8J
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p1123 LPSDFKTIL 7/8 10/11 2/2 T2-B7*, JY +
A*0101 p325 YAETKHFLY ND 1/2 ND ND EVB-DDU*, MOU, AKR + [72]
A*0301 p973 KLFGVLRLK ND 2/3 2/2 ND T2-A3*, U266, SKMES1, NHL, SK-MEL-2 ND [73]
2/6 4/7 ND ND + [69]
A*2401 p324 VYAETKHFL 2/3 (pDNA hTRT) 2/17 9/72 ND EBV-PBMC*, KH88, MEG01, OUN1, HepG2, 
HuH6, HuH7
+ [74–76]
p461 VYGFVRACL 3/3 (pDNA hTRT) 3/17 5/72 + EBV-PBMC*, HepG2, HuH6, HuH7 +
p1088 TYVPLLGSL 3/3 (pDNA hTRT) 0/13 6/72 ND [74–76]
p845 CYGDMENK
L
2/3 (pDNA hTRT) 0/13 6/72 ND
p637 DYVVGARTF 2/3 (pDNA hTRT) 0/11 9/72 ND [76]
p167 AYQVCGPPL 1/3 (pDNA hTRT) 0/11 9/72 ND
R/T: responders/total, Tet: Tetramer staining, ND: Not Done
*, denotes target cells pulsed with corresponding peptide
Table 2: Identification, Analysis and Characterization of HLA-restricted Telomerase Peptide (Continued)J
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Table 3: In Vitro CD8 T Cell Response against Telomerase Peptides in Cancer Patients
HLA Allele hTRT peptide Tumor type Killing of tumor cells Tumor infiltrating 
lymphocytes
Cancer Patient in vit-
roPBMC immunization R/T
Ref.
Autologous primary tumor 
cells
Established 
tumor cell lines
A2 p540 Prostate ND T2*, LnCap ND 6/9 (66%) [30]
Melanoma ND T2* ND 1/4 (25%) (unpublished data)
Hematological malignancies 
and advanced prostate
NHL ND ND 5/6 (83%) [73]
Prostate, Breast, Lung, Gastric, 
NHL, Liver
Prostate cancer cells ND ND 21/23 (91%) [67]
Breast ND ND ND 11/14 (79%) [69]
Colorectal Colorectal cancer cells ND ND 5/37 (13%) [68]
pY572 Prostate ND T2* ND 5/8 (62%) (unpublished data)
p865 Colorectal Colorectal cancer cells ND ND 4/37 (11%) [68]
Breast ND ND ND 6/14 (43%) [69]
Prostate ND T2* ND 3/6 (50%) (unpublished data)
Melanoma 2/3 (67%)
B7 p1123 Prostate ND T2-B7* ND 2/2 (100%) [70]
A3 p973 Breast U266, SK-MES-1, SK-MEL-2, NHL T2-A3*, ND 4/7 (57%) [69]
A24 p1008 Liver ND HepG2, HuH6 and 
HuH7 (Hepatoma)
ND 6/72 (8%) [76]
p845 6/72 (8%)
p167 9/72(13%)
p461 + 5/72 (7%)
p324 ND 9/72 (13%)
p637 9/72 (13%)
R/T: responders/total, ND: Not done
*, denotes target cells pulsed with corresponding peptideJ
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Table 4: Human Telomerase Reverse Transcriptase Clinical Trials
Clinical Trials Vaccine Type Cancer type HLA Immune monitoring Responding patients Ref.
Phase 1 Renal tumor mRNA transfected DCs Metastatic renal carcinoma (stage 
IV)
No restriction ELISPOT, 51Cr-assay 6/7 (86%) [45]
Phase 1 p540 in IFA Metastatic Cancer (Renal, 
melanoma, colon)
HLA-A2+ Tetramer staining, IFNγ secretion 7/14 (50%) [46]
Phase 1 p540 in KLH DCs Hormone-independent prostate 
Cancer
HLA-A2+ Tetramer staining, ELISPOT, Ag-
specific lymphocyte proliferation assay
2/5 (40%) [47]
Metastatic breast cancer HLA-A2+ 2/2 (100%)
Phase 1 Autologous transgenic B lymphocyes (p540 and 
pY572)
Androgen-Independent prostate 
cancer
HLA-A2+ Tetramer staining, Expansion of 
peptide-reactive CTL, 51Cr-assay
10/15 (67%) [51]
Phase 1 hTRT mRNA-transfected DCs Metastatic prostate cancer No restriction ELISPOT, 51Cr-assay, Ag-specific 
proliferation assay
8/9 (89%) [50]
Phase 1 p540, p613 (HLA-DR, -DQ -DP) and GM-CSF Non-small cell lung cancer No restriction 51Cr-assay, lymphocyte proliferation 
assay
11/24 (46%) response to p611 [48]
No restriction 2/24 (8%) response to p540
R/T, Responders/TotalJournal of Translational Medicine 2007, 5:12 http://www.translational-medicine.com/content/5/1/12
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prostate cancer patients vaccinated with dendritic cells
pulsed with p540 plus KLH [47]. A complete response was
observed in one patient with stage IIIA non-small cell lung
carcinoma at the time of vaccination [48]. Interestingly, in
this patient a telomerase specific T cell response in the
blood could be documented only after the first booster
injection but not subsequently.
Collectively, this first round of clinical trials demonstrated
vaccination against telomerase is safe and that a specific
immunological response can be induced in vivo, even
though much work needs to be performed to better char-
acterize phenotypically and functionally the T cell
response one obtains in vivo.
The UCSD Trial
We will summarize herein the main outcome of a Phase 1
telomerase cancer vaccine trial held between June 2003
and January 2005 at UCSD [51,52]. In this trial, we uti-
lized a new approach to vaccination aimed at optimizing
the host capacity to generate effective T cell responses by
synchronizing the activation of T cells within parameters
of space, time and antigen dose as discussed in (for review
see [53]). The vaccine was ultimately designed to generate
CD8 T cell responses against p540 and p572. We used pri-
mary B lymphocytes transgenic for non-viral DNA as a
source of APC [54], an approach termed "transgenic lym-
phocyte immunization." This relies on the fact that B lym-
phocytes spontaneously internalize plasmid (p)DNA [55]
an event that turns them into efficient APCs. We observed
that in the first 24 hours following pDNA internalization,
B lymphocytes undergo antigen synthesis and up-regula-
tion of costimulatory molecules, making them a new form
of genetically programmed APC [53]. In vitro studies had
shown that transgenic B lymphocytes as the only source of
APC activates both CD4 and CD8 T cells, albeit the latter
required T cell help [56]. In vivo studies had shown that
the intravenous (i.v.) injection of transgenic lymphocytes
in small numbers is highly effective in inducing both CD4
and CD8 T cell responses [54,57,58]. The success of these
studies owes in all likelihood to the fact that after i.v.
injection, transgenic B lymphopcytes localize in second-
ary lymphoid organs, the spleen and lymph nodes. Thus,
the advantage of direct transgenic lymphocyte immuniza-
tion is that it genetically programmed APC to the site of
immune induction (for review see [53]).
Fifteen patients with hormone resistant prostate cancer
were vaccinated by i.v. injection of autologous transgenic
lymphocytes. The median age was 73, with median per-
formance status of 1, and a median pre-treatment PSA of
148. All but three patients had metastases in bone and/or
lymph node. Two patients had recurrent local disease
only, and one had PSA-only disease. Patients were divided
into five cohorts of three patients each. Cohort 1–3
received a single injection of transgenic lymphocytes (104
– 106), respectively. Cohort 4a and 4b received two injec-
tions of 5 × 105transgenic lymphocytes one month apart.
In cohort 4a, the second injection utilized freshly pre-
pared transgenic lymphocytes whereas in cohort 4b the
booster vaccination was performed with frozen-thawed
cells. Infusions were well tolerated with no toxicity. Using
a sensitive RT-PCR (1–10 positive cells/106  cells) the
transgene could not be amplified from blood lym-
phocytes either hours, days or weeks following injection.
i) Transgenic lymphocyte immunization induced tetramer+ CD8 T 
cells
Tetramer staining was used to assess induction of CD8 T
cell specific for hTRT p540 and pY572. None of the three
patients in Cohort 1 had detectable tet540 or tetY572-reac-
tive CD8 T lymphocytes in their blood when examined by
FACS ex vivo. However, in one patient (#103) tetramer-
positive CD8 T cells were rapidly expanded from PBMC of
the day 56 blood draw. A response against p540 but not
pY572 was visible in all three patients in Cohort 2. Tet540
positive CD8 T cells were maximal on day 28 in two
patients and on day 21 in the third patient (#106) (Figure
1A). All patients in Cohort 3 had detectable tet540
response and to a lesser degree a tetY572 response. Restim-
ulation of the day 56 blood draw with p540 caused rapid
expansion of tet540-reactive CD8 T lymphocytes (Figure
1B). Thus, a single immunization with transgenic lym-
phocytes induced tet540 CD8 T cells detectable ex vivo in
Cohort 2 and 3. In all but two patients, peptide re-stimu-
lation in vitro expanded CD8 T lymphocytes of the day 56
blood draw suggesting that immunization had likely
expanded the pool of CD8 T cells specific for p540. On the
other hand, no tetY572 CD8 T cells by ex vivo FACS staining
were observed. However, tetY572-reactive CD8 T lym-
phocytes were expanded in vitro by restimulation of the
day 56 blood draw lymphocytes in one out of three
patients in each cohort. Collectively, after single injection,
tet540 CD8 T cells were detected in 6/9 and tetY572 CD8 T
cells in 0/9 patients. After in vitro restimulation on day 56,
tet540 CD8 T cells were expanded in 7/9 and tetY572 CD8 T
cells in 3/9 patients.
The effect of a second injection four weeks after priming
was investigated in six patients (cohort 4a and 4b). An
overall increase in tetramer-positive CD8 T lymphocytes
13 days after the second injection (day 43) yielded a mod-
est increment in the number of circulating tet540 CD8 T
cells in all six patients (40 ± 14/104 CD8 T cells on day 30
vs. 80 ± 29/104 CD8 T cells on day 43). A modest incre-
ment in tetY572 CD8 T cells occurred in 3/6 patients (26 ±
16/104 CD8 T cells on day 30 vs. 84 ± 49/104 CD8 T cells
on day 43). However, when lymphocytes of the day 43
blood draw were restimulated in culture with p540 a dis-
tinct expansion was observed in two patients of cohort 4aJournal of Translational Medicine 2007, 5:12 http://www.translational-medicine.com/content/5/1/12
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(Figure 2A and Figure 2B). Figure 2A also shows no expan-
sion using the day 28 blood harvest suggesting that the
expansion documented 15 days after the booster injection
was likely the result of the second vaccine injection. Tet540
CD8 T cells could not be expanded from lymphocytes of
the day 85 blood draw. The second injection had a visible
effect on the expansion of tetY572-positive CD8 T lym-
phocytes in four patients, three in cohort 4a and one in
cohort 4b. The expansion of tetY572-positive CD8 T lym-
phocytes was most consistently observed using lym-
phocytes of the day 85 blood draw (Figure 3A and 3B).
This suggests that in the same patient there may be differ-
ent in vivo kinetics of CD8 T lymphocytes in response to
p540 and pY572 immunization. Collectively, after the
second injection whereas tet540 CD8 T cells were expanded
in culture in 3/6 patients on day 43 and 0/6 patients and
on day 85, tetY572 CD8 T cells were expanded in 4/6
patients both on day 43 and 85.
CTL responses were sought in one patient in each cohort
to probe the functionality of tetramer-positive CD8 T lym-
phocytes. In cohort 1, patient #103 had a small but spe-
cific lysis of T2 pulsed with p572 (42% vs. 19% on control
targets) but not of T2 cells pulsed with p540. In cohorts 2
and 3, lysis of target cells pulsed with peptide was compa-
rable to lysis of non-pulsed cells arguing for the expansion
of NK cells. The two patients in cohort 4b lysed T2 target
cells pulsed with p540 but not p572. In one case in cohort
4a, CTL reactive with p540 (Figure 4 upper panel) also
lysed the HLA-A2+ MCF7 tumor cells (Figure 4 lower
panel) but not control HLA-A2- PC3 cells. Although non-
specific lysis was observed at the highest E:T ratio, this
Detection of tet-positive CD8 T lymphocytes after single vaccination with transgenic B lymphocytes Figure 1
Detection of tet-positive CD8 T lymphocytes after single vaccination with transgenic B lymphocytes. (A). Ex vivo detection of 
tet540-positive CD8 T cell responses on day 14, 21 and 28 in vaccines of cohort 2 who received a single vaccine injection of 
105transgenic B lymphocytes. (B) Example of expansion of tet540-positive CD8 T cell responses after in vitro peptide restimula-
tion in patient 107 who received a single vaccine injection of 106transgenic B lymphocytes. R – restimulation in culture followed 
by the number of restimulations.
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waned, decreasing the E:T ratio implying specific recogni-
tion of the 540 peptide in both instances.
ii. No untoward effects on circulating lymphocyte levels
Since telomerase activity has been reported in activated B
and T lymphocytes [59-61], it was important to monitor
changes in the number of circulating B and T lymphocytes
longitudinally through the end of the short-term follow-
up (Figure 5). The proportion of circulating B lym-
phocytes (CD19+) (panels A and B) and CD4 T lym-
phocytes (panels E and F) was substantially unchanged
over the corresponding values of the pre-immunization
time point, irrespective of the dose and number of injec-
tions, through the end of the short-term follow-up. Simi-
larly, the proportion of circulating CD8 T lymphocytes in
patients remained within a range comparable to that of
the pre-immunization time point (time zero) through the
end of the short term follow up period (panels C and D)
and even though in patients who were given two injec-
tions a negative trend showed at the end of the observa-
tion period (panel D) even in patients who were given two
injections. A non-parametric test using Spearman correla-
tion coefficients of a global hypothesis of non-zero trend
of mean CD19, CD4, or CD8 values over time after dose
administration at study day 0, for cohorts 1–3 and sepa-
rately for cohorts 4a-4b, each adjusted for multiple test-
ing, yielded a non-significant result. This suggests that
immunization against hTRT using transgenic lymphocytes
does not affect the number of lymphocytes in the periph-
eral blood.
Detection of tet540-positive CD8 T lymphocytes after booster vaccination with transgenic B lymphocytes Figure 2
Detection of tet540-positive CD8 T lymphocytes after booster vaccination with transgenic B lymphocytes. (A). Tet540-positive 
CD8 T cell responses, ex vivo and after in vitro peptide restimulation on day 28 and 43, in subject #115 of cohort 4b who 
received an injection of freshly prepared transgenic B lymphocytes at the dose of 0.5 × 105 followed one month later by a sim-
ilar dose of transgenic lymphocytes. R – restimulation in culture followed by the number of restimulations.
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iii. Clinical response
No formal PSA responses were found. However, at a more
accurate analysis, the PSA values distinguished three
groups: In the first group (5/15) in which the PSA was
considered stable the variation was < ± 25%. In the second
group (6/15) the PSA value increased over the pre-treat-
ment value but at the end of the short-term follow-up was
less than double the starting value. In the third group (4/
15) the PSA values doubled during the short-term follow-
up.
Conclusion
With this review article, it was our intent to provide an his-
torical perspective of the discovery of telomerase as the
first common cancer antigen, describing the steps that in
quick progression took the process from the bench to the
bedside. As described, the field developed quickly and the
transition from the test tube to Phase 1 trials has been a
rapid one.
With respect to the preclinical phase, one basic prerequi-
site in the successful selection of telomerase peptides was
an element of empiricism. Validation of potentially
immunogenic peptides depended on a number of criteria
among which good binding to the MHC molecule, while
necessary, was just the initial one. One important result
out of the in vitro studies was that humans forms a resid-
ual CD8 T cell repertoire against telomerase.
Contrary to our original prediction, the residual CD8 T
cell repertoire against telomerase in cancer patients was
found to be conserved as in normal individuals. The fact
Detection of tet572-positive CD8 T lymphocytes after booster vaccination with transgenic B lymphocytes Figure 3
Detection of tet572-positive CD8 T lymphocytes after booster vaccination with transgenic B lymphocytes. (A). Tet572-positive 
CD8 T cell responses, ex vivo and after in vitro peptide restimulation, in patient #112 of cohort 4a who received two injections 
of transgenic freshly prepared lymphocytes at the dose of 0.5 × 105 each one month apart. (B). Detection of tet572-positive 
CD8 T cell responses, ex vivo and after in vitro peptide restimulation, in patient #115 of cohort 4b who received an injection of 
freshly prepared transgenic B lymphocytes at the dose of 0.5 × 105 followed one month later by a similar dose of transgenic 
lymphocytes.Journal of Translational Medicine 2007, 5:12 http://www.translational-medicine.com/content/5/1/12
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that equal or greater expansion in vitro of CD8 T cells spe-
cific for telomerase peptides was found in cancer patients
as compared to normal individuals indicates that periph-
eral tolerance does not affect CD8 T cells specific for this
self tumor antigen in a way that prevents these cells from
being reactivated in vitro by peptide stimulation. Equally
unimpeded seemed the activation and expansion of CD8
T cell precursors in vivo as far as one can generalize from
HLA-A2+ cancer.
Given the widespread expression of telomerase in tumor
cells of different origin and type, it ultimately it was not
surprising that the same CTL could lyse tumor cells of dif-
ferent type and origin. Since this has been verified using
CTL generated in normal individuals [29] as well as in
cancer patients [30], a reasonable conclusion is that the
fine specificity of the residual repertoire in cancer patients
does not differ from that of normal individuals, suggest-
ing that peripheral tolerance does not result in a preferen-
tial expansion of CD8 T cells reactive with that tumor. In
other words, processing and presentation of a given tel-
omerase peptide is fundamentally similar in different
types of cancer.
Two groups have casted doubts on whether hTR p540 is
processed and presented in cancer cells. Ayyoub et al [62]
failed to demonstrate processing of p540 by purified
human proteasome or immunoproteasome in vitro. In the
same study these authors failed to demonstrate lysis of
three hTRT-positive melanoma cell lines while the same
cll lines pulsed with synthetic p540 were killed excluding
an intrinsic refractoriness to lysis or defective HLA expres-
The cytotoxic activity of CD8 T cells expanded in vitro (R4) from lymphocytes of subject #112 of cohort 4a who received two  injections of freshly prepared transgenic lymphocytes at the dose of 0.5 × 105 each one month apart Figure 4
The cytotoxic activity of CD8 T cells expanded in vitro (R4) from lymphocytes of subject #112 of cohort 4a who received two 
injections of freshly prepared transgenic lymphocytes at the dose of 0.5 × 105 each one month apart. Upper panel: lysis of T2 
cells with (close symbols) or without (open symbols) p540. Lower panel: lyses of MCF-7 (open symbols) or PC3 (close sym-
bols) tumor cells. Data in both panels refer to a single experiment where the values of triplicate wells were within 5% variation.
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sion. In a second report Parkhurst et al [46] was unable to
document specific recognition of hTR-positive melanoma
and renal cell carcinoma tumor cells by vaccine-induced
CTL. These authors also failed to visualize the HLA-A2-
p540 complex at the cell surface of melanoma cell lines
using an anti-complex antibody. However, since the affin-
ity of this antibody is low and the minimum number of
HLA-A2-p540 complexes sufficient and necessary for sur-
face staining visualization is unknown, the significance of
these negative results remains unclear. In contrast studies
from a variety laboratories have doacumented lysis of
tumor cells The existence of these negative reports should
foster new studies to assess the reason(s) for this discrep-
ancy among different laboratories.
Safety and potential for harmful autoimmunity were plau-
sible concerns of telomerase vaccination in humans. An in
depth discussion of this issue can be found in [8]. Telom-
erase is absent or undetectable in most somatic cells
[16,17,28] and it becomes detectable in mitotically-active
cells in normal tissues [63]. Indeed telomerase activity
was documented in fractions of leukocytes enriched for B
cells, T cells and monocytes [25] and in proliferating
hemopoietic stem cells concomitantly [64]. Germinal
center B lymphocytes express telomerase at high levels
(~100 fold the levels found in naïve and memory T cells
[59] and in vitro activation with anti-CD40 antibodies and
IL-4 [59] activates telomerase in B lymphocytes. Similarly,
in primary T lymphocytes telomerase activity is highly
Longitudinal survey of circulating B and T lymphocytes in vaccinated patients during the short term follow-up Figure 5
Longitudinal survey of circulating B and T lymphocytes in vaccinated patients during the short term follow-up. B lymphocytes 
(CD19+) in cohorts 1–3 (A) and in cohorts 4a and 4b (B). CD8 T lymphocytes in cohorts 1–3 (C) and in cohorts 4a and 4b (D). 
CD4 T lymphocytes in cohorts 1–3 (E) and in cohorts 4a and 4b (F). Data were analyzed and plotted as described in Materials 
and Methods, and are expressed as the % variation from pre-vaccination value for each subject.
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inducible by activation through CD3, with or without
similar CD28 co-stimulation [65]. Thus, in both B and T
lymphocytes, telomerase expression is activation-depend-
ent and correlates with cell proliferation. Notwithstand-
ing these considerations, experimental in vitro data
suggested that CTL specific for the HLA-A2 restricted
p540, p865 or py572 peptides do not lyse bone marrow-
derived HLA-A2+ CD34+ cells [30], activated T cells [66] or
CD40-activated B lymphocytes [49]. In line with these in
vitro studies, it was not surprising that telomerase vaccina-
tion of cancer patients did not yield signs of autoimmune
attack on normal cells. The Phase 1 trials performed to
date show telomerase vaccination to be safe. In the UCSD
trial, we found that the levels of circulating B and T lym-
phocytes did not decrease from the pre-vaccination value
(Figure 5). Collectively, the existing information permits
us to provisionally conclude that the risk of autoimmu-
nity following telomerase vaccination is minimal and
while continuous surveillance is appropriate, excessive
concerns are not.
In summary, telomerase as a candidate cancer vaccine has
been validated during the past six years. At this time, con-
clusions can be made with respect to issues of great funda-
mental interest and immunological significance. For
instance, it is clear that central and peripheral tolerance
against this self-antigen do not represent an obstacle to
expansion of specific CD8 T cell precursors by vaccination
even though the affinity of these T cells was not studied.
Precursor CD8 T cells against telomerase in cancer
patients can be expanded in vivo by various vaccine
approaches. Finally, it appears that within the confines of
the regimens of immunization tested so far, no untoward
effects against normal cells should be expected and that
the risk of autoimmunity is minimal. From only Phase 1
trials, it is premature to assess the clinical benefit of telom-
erase vaccination. In the future, it will be important to
compare various approaches to expand the pool of telom-
erase specific CD8 T cells in vivo in cancer patients with
respect to the type of CD8 T cells they expand and their
clinical response.
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